ObsEva, Merck Serono ink license agreement

Friday, August 30, 2013 02:23 PM

ObsEva, a Swiss-based, specialty biopharmaceutical company, signed a licensing agreement with Merck Serono, the biopharmaceutical division of Germany-based Merck, granting ObsEva worldwide development and commercialization rights to certain Merck Serono compounds for preterm labor. The details of the agreement were not disclosed. The funding will allow ObsEva to undertake the development of these compounds.

MS Ventures, the corporate venture capital fund of Merck Serono, has taken a minority equity stake in the company. Jasper Bos, Ph.D., will represent MS Ventures on ObsEva's board of directors. Rafaèle Tordjman M.D., Ph.D., managing partner at Sofinnova Partners, Jim Healy M.D., Ph.D., general partner at Sofinnova Ventures and Kim Dueholm, Ph.D., partner at Novo, will serve on the board, with Ernest Loumaye M.D., Ph.D., co-founder and chief executive officer of ObsEva.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs